Adavosertib

TNBC patient-derived xenograft (PDX) models were created using fresh tumour samples implanted in nude mice, treated with olaparib or adavosertib, and analyzed for drug sensitivity. A mathematical model incorporating resistance was developed to describe tumour growth dynamics, with parameters fitted using non-linear mixed effects (NLME). The model was validated using combination therapy data and transcriptomic features to identify potential biomarkers of resistance. Survival analysis was conducted to assess the impact of identified genes on treatment outcomes.

Researchers use mitochondria transfer to boost T cell efficacy in cancer immunotherapy, turn mice transparent with food dye for real-time imaging, engineer Toxoplasma gondii to deliver proteins across the blood-brain barrier, activate oncogenic signaling to make cancer cells vulnerable to stress response inhibitors, and design 'antinuclear missile' antibodies to target cancer cell nuclei.